AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	954	74191-85-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: doxazosin doxazosin mesylate doxazosine doxazosin mesilate	A prazosin-related compound that is a selective alpha-1-adrenergic blocker. Molecular weight: 451.48 Formula: C23H25N5O5 CLOGP: 3.58 LIPINSKI: 0 HAC: 10 HDO: 1 TPSA: 112.27 ALOGS: -2.76 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

doxazosin
doxazosin mesylate
doxazosine
doxazosin mesilate

A prazosin-related compound that is a selective alpha-1-adrenergic blocker.

Molecular weight: 451.48
Formula: C23H25N5O5
CLOGP: 3.58
LIPINSKI: 0
HAC: 10
HDO: 1
TPSA: 112.27
ALOGS: -2.76
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.59 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	10 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	63 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.669		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	9.016		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	23.121	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	9.840	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	6.420	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	19.930	%	High	1
herg	hERG pIC50	5.547	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	4.498	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	32.734	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	4.430	%	High	1
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAP3K21,MAPK10,MAPK7,MET,PDK2,PDK4,PIK3CA,PIK3CD,PIK3CG,PRKDC	20
kinase-selectivity-class	PRKDC,TTK	2
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	16.711		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	52.119		High	1
mppb	Mouse plasma protein binding (% unbound)	6.360		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	33.113		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1		High	1
pppb	Pig plasma protein binding (% unbound)	15.790	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	34.995	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	42.570	%	High	1
rppb	Rat plasma protein binding (% unbound)	4.960	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	5.236	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Nov. 2, 1990	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	187.46	13.44	148	23964	64816	90539519
Hyponatraemia	185.17	13.44	202	23910	133336	90470999
Hypotension	184.74	13.44	319	23793	325078	90279257
Syncope	181.03	13.44	199	23913	132464	90471871
Acute kidney injury	142.65	13.44	283	23829	320104	90284231
Drug interaction	132.54	13.44	252	23860	276201	90328134
Hypertensive crisis	118.05	13.44	68	24044	17716	90586619
Renal impairment	96.10	13.44	129	23983	105292	90499043
Angioedema	87.84	13.44	97	24015	64779	90539556
Blood pressure increased	84.97	13.44	172	23940	197045	90407290
Lip swelling	74.68	13.44	70	24042	38540	90565795
Bradycardia	73.97	13.44	101	24011	83746	90520589
Drug intolerance	71.19	13.44	16	24096	447575	90156760
Arthropathy	67.16	13.44	9	24103	366233	90238102
Glossodynia	66.54	13.44	5	24107	321774	90282561
Bladder prolapse	66.21	13.44	24	24088	2131	90602204
Urinary incontinence	64.89	13.44	64	24048	37502	90566833
Contraindicated product administered	63.39	13.44	6	24106	320133	90284202
Orthostatic hypotension	60.91	13.44	65	24047	41762	90562573
Dizziness	60.69	13.44	313	23799	588971	90015364
Treatment failure	59.37	13.44	6	24106	303922	90300413
Renal artery stenosis	58.61	13.44	22	24090	2155	90602180
Rectal prolapse	57.74	13.44	22	24090	2245	90602090
Systemic lupus erythematosus	57.40	13.44	13	24099	361883	90242452
Cardiospasm	55.29	13.44	24	24088	3422	90600913
Palmoplantar keratoderma	54.88	13.44	24	24088	3483	90600852
Presyncope	54.59	13.44	54	24058	31751	90572584
Gallbladder polyp	54.44	13.44	17	24095	954	90603381
Therapeutic product effect decreased	52.88	13.44	6	24106	277565	90326770
Sopor	52.17	13.44	47	24065	24597	90579738
Metabolic acidosis	52.04	13.44	69	24043	55607	90548728
Atrial tachycardia	51.01	13.44	27	24085	5963	90598372
Renal failure	50.25	13.44	109	24003	130898	90473437
Hypoglycaemia	49.70	13.44	76	24036	69772	90534563
Sleep terror	49.34	13.44	24	24088	4440	90599895
Muscle twitching	48.96	13.44	45	24067	24157	90580178
Pruritus genital	48.87	13.44	24	24088	4534	90599801
Loss of consciousness	48.54	13.44	112	24000	140126	90464209
Hepatic enzyme increased	47.98	13.44	18	24094	360718	90243617
Blood creatinine increased	47.94	13.44	92	24020	101294	90503041
Tubulointerstitial nephritis	47.19	13.44	45	24067	25298	90579037
Duodenal ulcer perforation	47.01	13.44	3	24109	221285	90383050
Wound	45.85	13.44	12	24100	302968	90301367
Sinus bradycardia	45.40	13.44	37	24075	16915	90587420
Tension headache	45.31	13.44	27	24085	7482	90596853
Diplopia	44.25	13.44	46	24066	28668	90575667
Carotid artery occlusion	44.09	13.44	25	24087	6317	90598018
Blood urea increased	43.81	13.44	47	24065	30366	90573969
Glomerular filtration rate decreased	43.35	13.44	36	24076	16896	90587439
Fibromyalgia	43.22	13.44	3	24109	206266	90398069
Vasculitis	41.70	13.44	40	24072	22653	90581682
Psoriatic arthropathy	40.92	13.44	6	24106	228329	90376006
Dehydration	40.73	13.44	129	23983	194318	90410017
Cardiac failure	39.60	13.44	89	24023	109407	90494928
Lactic acidosis	38.88	13.44	57	24055	50406	90553929
Discomfort	37.63	13.44	13	24099	274322	90330013
Immunisation	37.43	13.44	16	24096	2197	90602138
Thermal burn	37.42	13.44	23	24089	6739	90597596
Injection site inflammation	37.35	13.44	20	24092	4521	90599814
Ventricular tachycardia	37.04	13.44	39	24073	24669	90579666
Product use issue	36.83	13.44	21	24091	329898	90274437
Lower urinary tract symptoms	36.63	13.44	8	24104	106	90604229
Blood pressure inadequately controlled	36.57	13.44	22	24090	6202	90598133
Irritable bowel syndrome	35.93	13.44	6	24106	207442	90396893
Infusion related reaction	35.65	13.44	35	24077	416745	90187590
Ill-defined disorder	35.20	13.44	4	24108	184887	90419448
Hypokalaemia	35.14	13.44	95	24017	131021	90473314
Transient ischaemic attack	35.06	13.44	50	24062	43126	90561209
Type 2 diabetes mellitus	34.93	13.44	6	24106	203238	90401097
Cardiac failure congestive	34.33	13.44	79	24033	98615	90505720
Impaired healing	34.07	13.44	10	24102	234189	90370146
Anosmia	34.02	13.44	25	24087	9823	90594512
Myocardial infarction	33.80	13.44	82	24030	105890	90498445
Swelling	33.80	13.44	37	24075	419021	90185314
Alopecia	33.42	13.44	50	24062	495021	90109314
Atrial fibrillation	33.03	13.44	94	24018	133517	90470818
Disorientation	32.79	13.44	49	24063	44065	90560270
Oedema peripheral	32.22	13.44	145	23967	257770	90346565
Vitamin D decreased	31.77	13.44	26	24086	11953	90592382
Pain of skin	30.79	13.44	29	24083	16053	90588282
Rheumatoid arthritis	30.37	13.44	31	24081	362583	90241752
Sinusitis	30.28	13.44	28	24084	343060	90261275
Musculoskeletal stiffness	30.17	13.44	21	24091	296511	90307824
Anaemia	29.92	13.44	178	23934	352624	90251711
Facial pain	29.60	13.44	26	24086	13156	90591179
Blood pressure decreased	29.48	13.44	63	24049	74832	90529503
Hypertensive encephalopathy	29.28	13.44	10	24102	745	90603590
Oesophagitis	29.07	13.44	29	24083	17220	90587115
Subarachnoid haemorrhage	28.16	13.44	29	24083	17875	90586460
Blood potassium increased	28.03	13.44	31	24081	20718	90583617
Liver injury	27.27	13.44	6	24106	170561	90433774
Blood cholesterol increased	26.61	13.44	11	24101	208001	90396334
Off label use	26.17	13.44	179	23933	1102073	89502262
Stomatitis	25.95	13.44	21	24091	274677	90329658
Loss of personal independence in daily activities	25.76	13.44	3	24109	136102	90468233
Vision blurred	25.72	13.44	76	24036	110217	90494118
Feeling cold	25.60	13.44	34	24078	27431	90576904
Bradyphrenia	25.57	13.44	19	24093	7593	90596742
Therapeutic product effect incomplete	25.22	13.44	10	24102	193886	90410449
Mucosal membrane hyperplasia	24.86	13.44	5	24107	43	90604292
Blood pressure diastolic decreased	24.68	13.44	33	24079	26793	90577542
Bursitis	24.68	13.44	3	24109	131651	90472684
Maternal exposure during pregnancy	24.64	13.44	36	24076	360027	90244308
Condition aggravated	24.60	13.44	79	24033	595466	90008869
Swollen tongue	24.59	13.44	44	24068	45912	90558423
Blood glucose increased	24.50	13.44	68	24044	95178	90509157
Subdural haematoma	24.46	13.44	26	24086	16619	90587716
Crush syndrome	24.19	13.44	7	24105	302	90604033
Pain	24.03	13.44	161	23951	996180	89608155
Serotonin syndrome	23.87	13.44	39	24073	37848	90566487
Blood uric acid abnormal	23.66	13.44	6	24106	156	90604179
Palpitations	23.57	13.44	85	24027	136643	90467692
Chronic kidney disease	23.04	13.44	45	24067	50146	90554189
Haematoma	23.00	13.44	39	24073	39009	90565326
Gastrointestinal disorder	22.57	13.44	21	24091	256666	90347669
Eye infarction	22.44	13.44	5	24107	73	90604262
Urine glucose/creatinine ratio increased	22.35	13.44	6	24106	196	90604139
Renin increased	22.20	13.44	6	24106	201	90604134
Confusional state	22.13	13.44	177	23935	386028	90218307
Hypomagnesaemia	21.56	13.44	36	24076	35552	90568783
Vertebrobasilar insufficiency	21.50	13.44	6	24106	227	90604108
Lethargy	21.36	13.44	50	24062	63089	90541246
Abdominal discomfort	21.36	13.44	61	24051	477267	90127068
Nasopharyngitis	21.32	13.44	48	24064	407056	90197279
Malignant hypertension	21.32	13.44	9	24103	1198	90603137
Eye pruritus	21.23	13.44	32	24080	28995	90575340
Daydreaming	21.17	13.44	7	24105	472	90603863
Post cardiac arrest syndrome	21.15	13.44	4	24108	24	90604311
Osteoarthritis	21.07	13.44	13	24099	195717	90408618
Clonus	20.78	13.44	15	24097	5735	90598600
Hypocalcaemia	20.70	13.44	39	24073	42329	90562006
Wrong patient	20.69	13.44	8	24104	849	90603486
Pemphigoid	20.66	13.44	18	24094	9008	90595327
Pericarditis	20.52	13.44	25	24087	270126	90334209
Infection	20.38	13.44	41	24071	362053	90242282
Wheezing	20.33	13.44	20	24092	238060	90366275
Product use in unapproved indication	19.85	13.44	37	24075	336199	90268136
Blood pressure systolic abnormal	19.53	13.44	25	24087	19453	90584882
Ophthalmic herpes zoster	19.41	13.44	11	24101	2777	90601558
Hallucination, visual	19.12	13.44	27	24085	23065	90581270
Fall	19.09	13.44	204	23908	481606	90122729
Cerebral infarction	18.99	13.44	29	24083	26567	90577768
Circulatory collapse	18.99	13.44	28	24084	24876	90579459
Hallucination	18.89	13.44	49	24063	65910	90538425
Use of accessory respiratory muscles	18.87	13.44	6	24106	357	90603978
Hyperreflexia	18.82	13.44	15	24097	6642	90597693
Oral discharge	18.69	13.44	5	24107	161	90604174
Thrombotic microangiopathy	18.69	13.44	22	24090	15721	90588614
Hypersensitivity	18.28	13.44	61	24051	454616	90149719
Exposure during pregnancy	18.17	13.44	22	24090	238388	90365947
Incontinence	18.02	13.44	20	24092	13415	90590920
Nephrogenic systemic fibrosis	17.85	13.44	12	24100	4096	90600239
Dyspnoea	17.83	13.44	331	23781	880624	89723711
Heart rate decreased	17.69	13.44	42	24070	53463	90550872
Renal atrophy	17.66	13.44	9	24103	1839	90602496
Joint range of motion decreased	17.63	13.44	7	24105	135636	90468699
Blindness	17.62	13.44	28	24084	26540	90577795
Blood pressure diastolic abnormal	17.59	13.44	24	24088	19857	90584478
Torticollis	17.56	13.44	10	24102	2548	90601787
Angiosclerosis	17.54	13.44	3	24109	9	90604326
Lung disorder	17.50	13.44	9	24103	149874	90454461
Renal salt-wasting syndrome	17.49	13.44	6	24106	453	90603882
Hyperhidrosis	17.28	13.44	77	24035	136228	90468107
Feeling abnormal	17.24	13.44	89	24023	167146	90437189
Jaundice	17.23	13.44	31	24081	32486	90571849
Azotaemia	17.19	13.44	13	24099	5335	90599000
Anaphylactoid reaction	16.94	13.44	12	24100	4456	90599879
Gait inability	16.80	13.44	9	24103	146447	90457888
Road traffic accident	16.77	13.44	4	24108	107622	90496713
Product monitoring error	16.75	13.44	12	24100	4532	90599803
Renal tubular necrosis	16.72	13.44	20	24092	14535	90589800
Tinnitus	16.66	13.44	36	24076	43066	90561269
Drug ineffective	16.63	13.44	264	23848	1384034	89220301
Vomiting	16.57	13.44	298	23814	787995	89816340
Prescribed overdose	16.51	13.44	3	24109	97622	90506713
Inflammation	16.43	13.44	14	24098	178578	90425757
Injury	16.36	13.44	17	24095	197332	90407003
Cognitive disorder	16.34	13.44	48	24064	69359	90534976
Gingival bleeding	16.34	13.44	20	24092	14883	90589452
Lower respiratory tract infection	16.23	13.44	26	24086	250633	90353702
Blood pressure fluctuation	16.11	13.44	40	24072	52373	90551962
Fasting	15.59	13.44	3	24109	20	90604315
End stage renal disease	15.54	13.44	15	24097	8556	90595779
Nephrotic syndrome	15.53	13.44	14	24098	7325	90597010
Urticaria	15.47	13.44	38	24074	312696	90291639
Limb injury	15.38	13.44	29	24083	31479	90572856
Adverse event	15.35	13.44	6	24106	117412	90486923
Post procedural hypotension	15.34	13.44	3	24109	22	90604313
Aortic stenosis	15.24	13.44	13	24099	6323	90598012
Swelling face	15.24	13.44	52	24060	81300	90523035
Nephrogenic anaemia	15.23	13.44	9	24103	2457	90601878
Metabolic myopathy	15.10	13.44	4	24108	124	90604211
Product residue present	15.06	13.44	11	24101	4280	90600055
Plasmapheresis	14.97	13.44	5	24107	348	90603987
Drug dispensed to wrong patient	14.89	13.44	5	24107	354	90603981
Weight increased	14.86	13.44	59	24053	417868	90186467
Anuria	14.83	13.44	19	24093	14799	90589536
Liver function test abnormal	14.79	13.44	38	24074	50807	90553528
Simple partial seizures	14.74	13.44	6	24106	729	90603606
Shock	14.69	13.44	27	24085	28751	90575584
Wound infection	14.65	13.44	5	24107	106397	90497938
Scrotal oedema	14.51	13.44	3	24109	30	90604305
Blood pressure systolic increased	14.36	13.44	41	24071	58304	90546031
Sleep disorder	14.33	13.44	19	24093	198011	90406324
Malaise	14.30	13.44	227	23885	585759	90018576
Duodenal ulcer	14.18	13.44	15	24097	9537	90594798
Electrocardiogram ST-T segment abnormal	13.88	13.44	5	24107	436	90603899
Familial periodic paralysis	13.82	13.44	4	24108	173	90604162
Gastrointestinal haemorrhage	13.80	13.44	54	24058	90194	90514141
Mobility decreased	13.58	13.44	29	24083	250705	90353630
Left ventricular hypertrophy	13.56	13.44	12	24100	6132	90598203
Polyuria	13.56	13.44	15	24097	10025	90594310

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Conjunctivitis allergic	276.59	11.66	133	46203	5778	42569221
Mycotic allergy	268.84	11.66	123	46213	4768	42570231
Mite allergy	268.29	11.66	124	46212	4922	42570077
Spirometry abnormal	265.96	11.66	124	46212	5022	42569977
Dust allergy	264.83	11.66	125	46211	5207	42569792
Normochromic normocytic anaemia	223.60	11.66	133	46203	8898	42566101
Arteriosclerosis	219.59	11.66	171	46165	17818	42557181
Asthma	184.14	11.66	279	46057	62035	42512964
Syncope	183.17	11.66	361	45975	99045	42475954
Arteriosclerosis coronary artery	174.47	11.66	152	46184	18525	42556474
Neuritis	170.87	11.66	98	46238	6122	42568877
Pulmonary vasculitis	167.53	11.66	97	46239	6169	42568830
Full blood count abnormal	164.38	11.66	182	46154	29694	42545305
Nodule	159.18	11.66	122	46214	12412	42562587
Off label use	150.09	11.66	293	46043	638042	41936957
Productive cough	138.51	11.66	221	46115	51346	42523653
Eosinophilic granulomatosis with polyangiitis	136.64	11.66	96	46240	8542	42566457
Neurological symptom	135.17	11.66	101	46235	9890	42565109
Sleep disorder due to a general medical condition	129.75	11.66	125	46211	17328	42557671
Obstructive airways disorder	119.55	11.66	141	46195	24618	42550381
Carotid arteriosclerosis	113.73	11.66	54	46282	2278	42572721
Wheezing	113.18	11.66	209	46127	54572	42520427
Respiratory symptom	113.12	11.66	95	46241	11011	42563988
Antineutrophil cytoplasmic antibody positive	112.53	11.66	66	46270	4299	42570700
Hypertensive crisis	109.56	11.66	90	46246	10116	42564883
Total lung capacity abnormal	108.84	11.66	65	46271	4378	42570621
Pulmonary alveolar haemorrhage	106.16	11.66	104	46232	14712	42560287
Orthostatic hypotension	101.98	11.66	145	46191	30425	42544574
Pulmonary fibrosis	85.25	11.66	124	46212	26557	42548442
Forced expiratory volume decreased	79.22	11.66	66	46270	7564	42567435
Capillaritis	77.42	11.66	41	46295	2187	42572812
Febrile neutropenia	70.53	11.66	59	46277	185644	42389355
Neutropenia	69.05	11.66	69	46267	199362	42375637
Thrombosis	68.28	11.66	196	46140	68315	42506684
Drug ineffective	67.01	11.66	407	45929	629790	41945209
Hypothyroidism	66.98	11.66	123	46213	31961	42543038
Renal cyst haemorrhage	66.94	11.66	26	46310	664	42574335
Vasculitis	66.94	11.66	91	46245	18303	42556696
Hyperkalaemia	66.91	11.66	216	46120	80242	42494757
Left ventricular hypertrophy	65.98	11.66	65	46271	9254	42565745
Blood pressure inadequately controlled	65.20	11.66	40	46296	2828	42572171
Presyncope	62.90	11.66	98	46238	22289	42552710
Haemoptysis	62.34	11.66	148	46188	46019	42528980
Rectal prolapse	57.23	11.66	22	46314	546	42574453
Loss of consciousness	57.13	11.66	225	46111	92129	42482870
Hypoxia	56.80	11.66	186	46150	69600	42505399
Drug abuse	55.82	11.66	22	46314	104749	42470250
Hypotension	54.82	11.66	472	45864	257159	42317840
Aortic valve incompetence	54.60	11.66	50	46286	6498	42568501
Primary hyperaldosteronism	53.97	11.66	16	46320	172	42574827
Dizziness	50.08	11.66	451	45885	248803	42326196
Oedema peripheral	50.02	11.66	285	46051	135791	42439208
Renal artery stenosis	49.34	11.66	31	46305	2286	42572713
Complications of transplanted kidney	48.85	11.66	43	46293	5307	42569692
Drug interaction	47.61	11.66	471	45865	266528	42308471
Middle insomnia	47.04	11.66	50	46286	7783	42567216
Aortic dilatation	42.40	11.66	25	46311	1644	42573355
SARS-CoV-2 antibody test positive	41.97	11.66	16	46320	388	42574611
Lung disorder	41.95	11.66	131	46205	47792	42527207
Abdominal wall haemorrhage	41.49	11.66	17	46319	501	42574498
Vena cava injury	40.75	11.66	15	46321	329	42574670
Product dose omission issue	40.34	11.66	66	46270	154299	42420700
Foetal exposure during pregnancy	39.94	11.66	3	46333	47308	42527691
Gastrointestinal tract mucosal pigmentation	39.67	11.66	17	46319	562	42574437
Vascular compression	38.77	11.66	15	46321	379	42574620
Vascular anastomotic haemorrhage	38.38	11.66	14	46322	299	42574700
Nephrectomy	38.20	11.66	19	46317	888	42574111
Disease progression	37.93	11.66	61	46275	143595	42431404
Hyperparathyroidism secondary	37.62	11.66	24	46312	1818	42573181
Blood creatinine increased	37.55	11.66	226	46110	109777	42465222
Bradycardia	37.49	11.66	188	46148	85296	42489703
Mucosal inflammation	36.84	11.66	5	46331	49369	42525630
Metabolic acidosis	36.74	11.66	132	46204	51726	42523273
Mycobacterium test positive	36.02	11.66	15	46321	461	42574538
Product use in unapproved indication	35.43	11.66	94	46242	184362	42390637
Aortic arteriosclerosis	34.93	11.66	35	46301	5085	42569914
Ventricular hyperkinesia	34.30	11.66	12	46324	226	42574773
Thrombocytopenia	34.30	11.66	100	46236	190179	42384820
Loss of personal independence in daily activities	33.76	11.66	125	46211	49691	42525308
Sepsis	33.62	11.66	108	46228	199226	42375773
Blood 25-hydroxycholecalciferol decreased	33.54	11.66	13	46323	330	42574669
Tricuspid valve incompetence	33.11	11.66	50	46286	11063	42563936
Hypertensive heart disease	32.50	11.66	25	46311	2555	42572444
Renal impairment	32.39	11.66	218	46118	110010	42464989
Right atrial enlargement	32.07	11.66	12	46324	276	42574723
Delayed graft function	32.03	11.66	25	46311	2610	42572389
Septic shock	31.36	11.66	32	46304	91640	42483359
Atrial fibrillation	31.33	11.66	259	46077	139334	42435665
Death	31.19	11.66	345	45991	470840	42104159
Inappropriate schedule of product administration	31.11	11.66	35	46301	95867	42479132
Hypochromasia	30.45	11.66	12	46324	319	42574680
Perineal cyst	30.11	11.66	11	46325	236	42574763
Multiple organ dysfunction syndrome	29.78	11.66	37	46299	96998	42478001
Drug ineffective for unapproved indication	29.42	11.66	7	46329	46156	42528843
Lipoprotein (a) increased	29.34	11.66	12	46324	352	42574647
Mitral valve thickening	29.32	11.66	13	46323	467	42574532
Biliary cirrhosis	29.06	11.66	10	46326	179	42574820
Intraductal papillary mucinous neoplasm	29.04	11.66	13	46323	478	42574521
Blood pressure increased	29.00	11.66	200	46136	101728	42473271
Therapeutic product effect incomplete	28.31	11.66	152	46184	70787	42504212
Pyrexia	28.29	11.66	283	46053	393759	42181240
Atrioventricular block first degree	28.11	11.66	35	46301	6456	42568543
Orthopnoea	28.06	11.66	32	46304	5385	42569614
Hypokalaemia	27.50	11.66	152	46184	71569	42503430
Angioedema	27.47	11.66	105	46231	42372	42532627
Pain in extremity	27.42	11.66	267	46069	150337	42424662
Lung diffusion test decreased	27.26	11.66	15	46321	864	42574135
Myocardial infarction	27.24	11.66	229	46107	123780	42451219
Floppy iris syndrome	27.21	11.66	11	46325	313	42574686
Melaena	26.91	11.66	98	46238	38648	42536351
Hyperparathyroidism	26.71	11.66	17	46319	1282	42573717
Tongue haemorrhage	26.60	11.66	14	46322	737	42574262
Haemodialysis	26.19	11.66	43	46293	10217	42564782
Subacute hepatic failure	26.19	11.66	8	46328	96	42574903
Product use issue	26.01	11.66	27	46309	76724	42498275
Electrocardiogram T wave inversion	25.92	11.66	21	46315	2313	42572686
Mean platelet volume increased	25.68	11.66	13	46323	631	42574368
Blood potassium increased	25.63	11.66	60	46276	18476	42556523
Urine flow decreased	25.63	11.66	17	46319	1376	42573623
Renal cyst	25.53	11.66	42	46294	9997	42565002
Atrioventricular block	25.50	11.66	41	46295	9574	42565425
Left ventricular enlargement	25.26	11.66	14	46322	818	42574181
Large intestine polyp	25.25	11.66	40	46296	9225	42565774
Scrotal oedema	25.24	11.66	19	46317	1880	42573119
Vertigo	24.81	11.66	88	46248	34259	42540740
Dyspnoea	24.58	11.66	642	45694	441979	42133020
Renin increased	24.30	11.66	9	46327	201	42574798
Myopathy	24.11	11.66	49	46287	13712	42561287
Cardiac autonomic neuropathy	24.07	11.66	7	46329	70	42574929
Erosive duodenitis	24	11.66	18	46318	1771	42573228
Blood pressure ambulatory increased	23.98	11.66	7	46329	71	42574928
Mitral valve incompetence	23.49	11.66	54	46282	16435	42558564
Spinal osteoarthritis	22.98	11.66	37	46299	8649	42566350
Diverticulum intestinal	22.84	11.66	28	46308	5085	42569914
Left atrial enlargement	22.42	11.66	14	46322	1021	42573978
Nocturia	22.26	11.66	44	46292	12068	42562931
Blood urea increased	21.98	11.66	82	46254	32711	42542288
Phaeochromocytoma	21.82	11.66	9	46327	270	42574729
Malignant neoplasm progression	21.75	11.66	54	46282	108346	42466653
Mean cell volume increased	21.73	11.66	24	46312	3899	42571100
Gravitational oedema	21.73	11.66	12	46324	696	42574303
Chronic kidney disease	21.48	11.66	105	46231	47136	42527863
Treatment failure	21.25	11.66	22	46314	62602	42512397
Adrenal cyst	21.22	11.66	8	46328	188	42574811
Nausea	21.17	11.66	304	46032	396495	42178504
Intervertebral disc space narrowing	21.13	11.66	14	46322	1131	42573868
Endoscopy upper gastrointestinal tract abnormal	21.10	11.66	6	46330	55	42574944
Angina pectoris	21.01	11.66	81	46255	32815	42542184
Actinic keratosis	20.98	11.66	27	46309	5149	42569850
Hypergastrinaemia	20.11	11.66	8	46328	218	42574781
Sprue-like enteropathy	19.95	11.66	11	46325	636	42574363
Infusion related reaction	19.92	11.66	22	46314	60784	42514215
Pain	19.61	11.66	171	46165	244677	42330322
Leukopenia	19.47	11.66	32	46304	74714	42500285
Intentional product use issue	19.42	11.66	30	46306	71803	42503196
Infection	19.38	11.66	60	46276	112008	42462991
Hepatic cytolysis	19.37	11.66	3	46333	26841	42548158
Spinal stenosis	19.34	11.66	29	46307	6377	42568622
Tooth avulsion	19.29	11.66	5	46331	31	42574968
Supine hypertension	19.03	11.66	9	46327	376	42574623
Shock hypoglycaemic	18.80	11.66	6	46330	84	42574915
Paraganglion neoplasm	18.60	11.66	4	46332	9	42574990
Glomerular filtration rate decreased	18.47	11.66	49	46287	16302	42558697
Agitation	18.22	11.66	26	46310	64288	42510711
Toxic neuropathy	18.03	11.66	10	46326	585	42574414
Duplicate therapy error	18.03	11.66	8	46328	288	42574711
CADASIL	17.89	11.66	6	46330	99	42574900
Bundle branch block left	17.70	11.66	28	46308	6448	42568551
Renal failure	17.64	11.66	236	46100	143490	42431509
Drug dependence	17.41	11.66	5	46331	29089	42545910
Rhabdomyolysis	17.08	11.66	144	46192	77875	42497124
Acute kidney injury	17.05	11.66	521	45815	366816	42208183
Glycosylated haemoglobin increased	16.97	11.66	41	46295	12883	42562116
Bursitis infective	16.95	11.66	10	46326	658	42574341
Hepatosplenomegaly	16.87	11.66	23	46313	4637	42570362
Device related bacteraemia	16.80	11.66	10	46326	669	42574330
Hypertension	16.74	11.66	265	46071	166939	42408060
Blood chloride increased	16.74	11.66	20	46316	3536	42571463
Dilatation ventricular	16.52	11.66	17	46319	2549	42572450
Pneumonia	16.50	11.66	342	45994	421807	42153192
Completed suicide	16.43	11.66	52	46284	96413	42478586
Myalgia	16.33	11.66	168	46168	95912	42479087
Myopathy toxic	15.99	11.66	10	46326	731	42574268
Respiratory failure	15.53	11.66	79	46257	128053	42446946
Swelling of eyelid	15.36	11.66	15	46321	2113	42572886
Xanthopsia	15.28	11.66	6	46330	158	42574841
Neuropathy peripheral	15.25	11.66	58	46278	101795	42473204
Toxic optic neuropathy	15.16	11.66	11	46325	1029	42573970
Spermatozoa progressive motility abnormal	14.77	11.66	4	46332	30	42574969
Pancytopenia	14.61	11.66	72	46264	117671	42457328
Microalbuminuria	14.49	11.66	10	46326	864	42574135
Vitamin D decreased	14.44	11.66	21	46315	4494	42570505
Kidney transplant rejection	14.13	11.66	30	46306	8653	42566346
Circulatory collapse	14.12	11.66	57	46279	23579	42551420
Clang associations	14.03	11.66	4	46332	37	42574962
Haematuria	13.90	11.66	109	46227	57690	42517309
Obstruction	13.87	11.66	17	46319	3086	42571913
Chronic fatigue syndrome	13.84	11.66	7	46329	339	42574660
Toxicity to various agents	13.84	11.66	171	46165	228965	42346034
Premature baby	13.82	11.66	4	46332	23149	42551850
Nephrogenic systemic fibrosis	13.78	11.66	18	46318	3483	42571516
High density lipoprotein decreased	13.75	11.66	19	46317	3878	42571121
Psoriatic arthropathy	13.69	11.66	5	46331	24962	42550037
Pulmonary embolism	13.69	11.66	194	46142	119418	42455581
Optic nerve disorder	13.67	11.66	9	46327	719	42574280
Blood potassium abnormal	13.66	11.66	13	46323	1773	42573226
Stomatitis	13.62	11.66	21	46315	50308	42524691
Benign prostatic hyperplasia	13.57	11.66	52	46284	21000	42553999
Anuria	13.48	11.66	35	46301	11497	42563502
Inappropriate affect	13.36	11.66	9	46327	747	42574252
Erectile dysfunction	13.26	11.66	58	46278	24855	42550144
Transaminases increased	13.02	11.66	10	46326	32875	42542124
Nephrogenic anaemia	12.93	11.66	15	46321	2571	42572428
Dermatosis	12.92	11.66	7	46329	391	42574608
Haemoglobin decreased	12.90	11.66	209	46127	132262	42442737
White blood cell count decreased	12.85	11.66	69	46267	110327	42464672
Coronary artery disease	12.75	11.66	101	46235	53619	42521380
Urinary retention	12.69	11.66	84	46252	42130	42532869
Cerebral haemorrhage	12.61	11.66	79	46257	38887	42536112
Hypochromic anaemia	12.60	11.66	10	46326	1070	42573929
Genital swelling	12.53	11.66	6	46330	258	42574741
Hyperuricaemia	12.48	11.66	30	46306	9394	42565605
Diastolic dysfunction	12.39	11.66	25	46311	6958	42568041
Lymphopenia	12.37	11.66	4	46332	21559	42553440
Prostatic haemorrhage	12.32	11.66	6	46330	268	42574731
Intentional product misuse	12.28	11.66	31	46305	61869	42513130
Arteriovenous fistula operation	12.28	11.66	5	46331	145	42574854
Jaundice hepatocellular	12.28	11.66	4	46332	60	42574939
Bronchopulmonary aspergillosis	12.27	11.66	3	46333	19426	42555573
Ventricular extrasystoles	12.08	11.66	37	46299	13353	42561646
Drug reaction with eosinophilia and systemic symptoms	11.92	11.66	17	46319	42058	42532941
Drug intolerance	11.91	11.66	46	46290	80378	42494621
Rash maculo-papular	11.81	11.66	14	46322	37489	42537510
Drug monitoring procedure not performed	11.72	11.66	7	46329	471	42574528
Visual field defect	11.68	11.66	20	46316	4918	42570081

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Syncope	385.19	11.55	523	62316	202013	110324447
Conjunctivitis allergic	342.70	11.55	134	62705	6797	110519663
Spirometry abnormal	339.41	11.55	125	62714	5372	110521088
Mite allergy	332.81	11.55	125	62714	5678	110520782
Dust allergy	332.34	11.55	126	62713	5875	110520585
Mycotic allergy	326.08	11.55	124	62715	5830	110520630
Normochromic normocytic anaemia	267.12	11.55	136	62703	12921	110513539
Arteriosclerosis	265.34	11.55	169	62670	24598	110501862
Hyperkalaemia	263.05	11.55	354	62485	135442	110391018
Hypertensive crisis	243.09	11.55	159	62680	24213	110502247
Arteriosclerosis coronary artery	229.12	11.55	155	62684	24963	110501497
Pulmonary vasculitis	226.18	11.55	98	62741	6462	110519998
Neuritis	221.19	11.55	100	62739	7299	110519161
Hypotension	216.85	11.55	722	62117	523127	110003333
Drug interaction	201.32	11.55	683	62156	499500	110026960
Orthostatic hypotension	178.61	11.55	204	62635	66045	110460415
Eosinophilic granulomatosis with polyangiitis	177.93	11.55	97	62742	10589	110515871
Full blood count abnormal	177.82	11.55	188	62651	55864	110470596
Neurological symptom	160.97	11.55	104	62735	15504	110510956
Acute kidney injury	156.87	11.55	745	62094	634685	109891775
Total lung capacity abnormal	149.98	11.55	66	62773	4517	110521943
Antineutrophil cytoplasmic antibody positive	146.66	11.55	67	62772	5009	110521451
Respiratory symptom	145.37	11.55	96	62743	14849	110511611
Productive cough	141.51	11.55	242	62597	114063	110412397
Pulmonary alveolar haemorrhage	139.20	11.55	105	62734	20045	110506415
Obstructive airways disorder	136.20	11.55	149	62690	46000	110480460
Off label use	131.00	11.55	428	62411	1499757	109026703
Nodule	128.37	11.55	123	62716	32508	110493952
Bradycardia	122.45	11.55	272	62567	155245	110371215
Renal impairment	121.65	11.55	305	62534	188140	110338320
Vasculitis	120.36	11.55	124	62715	35749	110490711
Presyncope	117.56	11.55	142	62697	48745	110477715
Hyponatraemia	116.91	11.55	329	62510	217324	110309136
Rectal prolapse	107.43	11.55	44	62795	2519	110523941
Loss of consciousness	104.69	11.55	296	62543	196010	110330450
Metabolic acidosis	102.78	11.55	195	62644	99549	110426911
Renal artery stenosis	100.84	11.55	47	62792	3679	110522781
Carotid arteriosclerosis	99.96	11.55	44	62795	3013	110523447
Capillaritis	99.28	11.55	41	62798	2398	110524062
Drug intolerance	98.76	11.55	54	62785	406458	110120002
Systemic lupus erythematosus	97.98	11.55	14	62825	254324	110272136
Psoriatic arthropathy	94.57	11.55	4	62835	196757	110329703
Pemphigus	92.24	11.55	8	62831	214562	110311898
Alopecia	92.22	11.55	46	62793	364707	110161753
Glossodynia	90.91	11.55	10	62829	221994	110304466
Blood creatinine increased	90.03	11.55	268	62571	182621	110343839
Hepatic enzyme increased	89.74	11.55	35	62804	320857	110205603
Forced expiratory volume decreased	89.55	11.55	68	62771	13108	110513352
Angioedema	87.53	11.55	181	62658	98319	110428141
Pain	86.17	11.55	268	62571	954687	109571773
Sleep disorder due to a general medical condition	86.15	11.55	126	62713	51986	110474474
Arthropathy	86.13	11.55	28	62811	287494	110238966
Contraindicated product administered	86.13	11.55	18	62821	248249	110278211
Thrombosis	85.44	11.55	190	62649	108472	110417988
Renal failure	85.33	11.55	303	62536	226271	110300189
Infusion related reaction	85.04	11.55	56	62783	381106	110145354
Left ventricular hypertrophy	84.86	11.55	66	62773	13178	110513282
Duodenal ulcer perforation	84.13	11.55	4	62835	177696	110348764
Treatment failure	83.04	11.55	27	62812	277207	110249253
Folliculitis	81.96	11.55	3	62836	167650	110358810
Renal cyst haemorrhage	80.95	11.55	26	62813	735	110525725
Atrial fibrillation	79.64	11.55	299	62540	229343	110297117
Haemoptysis	79.14	11.55	144	62695	71210	110455250
Helicobacter infection	77.58	11.55	7	62832	181870	110344590
Blood pressure inadequately controlled	76.59	11.55	50	62789	7583	110518877
Fibromyalgia	74.48	11.55	6	62833	170903	110355557
Dizziness	73.22	11.55	660	62179	697533	109828927
Product use issue	71.98	11.55	44	62795	311651	110214809
Rheumatoid arthritis	71.01	11.55	41	62798	299572	110226888
Blood pressure increased	70.99	11.55	313	62526	258060	110268400
Complications of transplanted kidney	70.43	11.55	47	62792	7395	110519065
Sinusitis	69.75	11.55	41	62798	296647	110229813
Hypothyroidism	69.57	11.55	138	62701	72761	110453699
Therapeutic product effect decreased	69.37	11.55	26	62813	244290	110282170
Oedema peripheral	69.31	11.55	369	62470	328291	110198169
Maternal exposure during pregnancy	67.70	11.55	30	62809	254853	110271607
Pericarditis	66.21	11.55	21	62818	219093	110307367
Hypoxia	64.86	11.55	191	62648	129324	110397136
Wound	64.82	11.55	26	62813	234411	110292049
Ill-defined disorder	64.37	11.55	7	62832	156846	110369614
Muscle injury	64.07	11.55	4	62835	140803	110385657
Stomatitis	64.01	11.55	37	62802	270205	110256255
Blood urea increased	63.61	11.55	113	62726	54844	110471616
Primary hyperaldosteronism	62.58	11.55	17	62822	263	110526197
Lip swelling	62.31	11.55	107	62732	50560	110475900
Drug ineffective	61.47	11.55	561	62278	1519979	109006481
Irritable bowel syndrome	61.03	11.55	10	62829	164205	110362255
Discomfort	60.70	11.55	23	62816	214684	110311776
Melaena	58.34	11.55	124	62715	68633	110457827
Glomerular filtration rate decreased	58.32	11.55	77	62762	28879	110497581
Aortic valve incompetence	58.24	11.55	49	62790	10932	110515528
Hypokalaemia	57.08	11.55	230	62609	182218	110344242
Bladder prolapse	54.52	11.55	23	62816	1419	110525041
Impaired healing	54.08	11.55	22	62817	196695	110329765
Cardiac failure	53.58	11.55	230	62609	187396	110339064
Hypoglycaemia	53.23	11.55	166	62673	115938	110410522
Nasopharyngitis	53.05	11.55	89	62750	394272	110132188
Rhabdomyolysis	52.33	11.55	169	62670	120232	110406228
SARS-CoV-2 antibody test positive	51.72	11.55	16	62823	399	110526061
Blood potassium increased	51.52	11.55	78	62761	33171	110493289
Infection	50.34	11.55	80	62759	362120	110164340
Musculoskeletal stiffness	50.10	11.55	51	62788	279771	110246689
Neutropenia	49.97	11.55	85	62754	374535	110151925
Vena cava injury	49.96	11.55	15	62824	337	110526123
Abdominal wall haemorrhage	49.74	11.55	18	62821	735	110525725
Renin increased	49.39	11.55	15	62824	351	110526109
Product use in unapproved indication	48.94	11.55	114	62725	447263	110079197
Sinus bradycardia	48.31	11.55	71	62768	29412	110497048
Bursitis	48.08	11.55	8	62831	129910	110396550
Scrotal oedema	47.97	11.55	22	62817	1659	110524801
Delayed graft function	47.96	11.55	30	62809	4227	110522233
Myocardial infarction	47.75	11.55	226	62613	191857	110334603
Vascular anastomotic haemorrhage	47.30	11.55	14	62825	299	110526161
Blood cholesterol increased	47.13	11.55	23	62816	184762	110341698
Febrile neutropenia	45.90	11.55	68	62771	316699	110209761
Chronic kidney disease	45.58	11.55	120	62719	76171	110450289
Middle insomnia	45.17	11.55	57	62782	20445	110506015
Aortic dilatation	44.79	11.55	23	62816	2223	110524237
Asthma	44.15	11.55	268	62571	250023	110276437
Mobility decreased	43.97	11.55	42	62797	237380	110289080
Dyspnoea	43.67	11.55	876	61963	1105996	109420464
Vitamin D decreased	42.37	11.55	43	62796	12172	110514288
Lip dry	42.27	11.55	4	62835	100079	110426381
Intentional product use issue	41.26	11.55	48	62791	247858	110278602
Mycobacterium test positive	41.14	11.55	15	62824	626	110525834
Hypersensitivity	41.00	11.55	107	62732	403891	110122569
Exposure during pregnancy	40.96	11.55	22	62817	167402	110359058
Sopor	40.82	11.55	74	62765	36472	110489988
Cerebral haemorrhage	40.67	11.55	104	62735	64864	110461596
Type 2 diabetes mellitus	39.54	11.55	26	62813	177206	110349254
Cardiac failure congestive	39.24	11.55	180	62659	150820	110375640
Abdominal discomfort	38.69	11.55	106	62733	393752	110132708
Product dose omission issue	38.48	11.55	78	62761	321704	110204756
Ventricular hyperkinesia	38.42	11.55	12	62827	309	110526151
Vascular compression	38.25	11.55	15	62824	766	110525694
Obesity	37.72	11.55	9	62830	113342	110413118
Blood 25-hydroxycholecalciferol decreased	37.62	11.55	13	62826	463	110525997
Gastrointestinal tract mucosal pigmentation	37.35	11.55	17	62822	1260	110525200
Perineal cyst	37.25	11.55	11	62828	233	110526227
Swelling	37.15	11.55	91	62748	350950	110175510
Gastrointestinal disorder	36.97	11.55	50	62789	241902	110284558
Erectile dysfunction	36.83	11.55	49	62790	18507	110507953
Mitral valve incompetence	36.61	11.55	67	62772	33262	110493198
Peripheral venous disease	36.51	11.55	3	62836	84114	110442346
Large intestine polyp	36.48	11.55	44	62795	15073	110511387
Hypertensive heart disease	36.37	11.55	26	62813	4570	110521890
Circulatory collapse	35.85	11.55	77	62762	42916	110483544
Tricuspid valve incompetence	35.57	11.55	55	62784	23818	110502642
Osteoarthritis	35.36	11.55	31	62808	182592	110343868
Benign prostatic hyperplasia	34.44	11.55	47	62792	18187	110508273
Grip strength decreased	34.41	11.55	3	62836	80171	110446289
Atrioventricular block	34.17	11.55	45	62794	16832	110509628
Gallbladder polyp	34.10	11.55	16	62823	1271	110525189
Hyperparathyroidism secondary	34.03	11.55	22	62817	3282	110523178
Atrioventricular block first degree	33.67	11.55	41	62798	14184	110512276
Nephrectomy	33.31	11.55	20	62819	2620	110523840
Left ventricular enlargement	33.29	11.55	14	62825	857	110525603
Erosive duodenitis	33.24	11.55	19	62820	2272	110524188
Orthopnoea	33.23	11.55	36	62803	10985	110515475
Renal cyst	33.06	11.55	46	62793	18126	110508334
Biliary cirrhosis	33.01	11.55	10	62829	232	110526228
Joint range of motion decreased	32.88	11.55	14	62825	121818	110404642
Right atrial enlargement	32.84	11.55	12	62827	504	110525956
Urine flow decreased	32.75	11.55	16	62823	1390	110525070
Lactic acidosis	32.26	11.55	121	62718	92690	110433770
Angina pectoris	32.26	11.55	93	62746	62202	110464258
Tubulointerstitial nephritis	32.03	11.55	85	62754	54199	110472261
Tongue haemorrhage	31.99	11.55	15	62824	1190	110525270
Urticaria	31.92	11.55	85	62754	318772	110207688
Aortic arteriosclerosis	31.71	11.55	35	62804	10903	110515557
Rash	31.67	11.55	306	62533	820658	109705802
Lower respiratory tract infection	31.63	11.55	56	62783	243050	110283410
Mitral valve thickening	31.55	11.55	13	62826	756	110525704
Wound infection	31.44	11.55	8	62831	96457	110430003
Haemoglobin decreased	30.65	11.55	244	62595	248483	110277977
Urinary incontinence	30.64	11.55	78	62761	48509	110477951
Intraductal papillary mucinous neoplasm	30.16	11.55	13	62826	846	110525614
Pulmonary fibrosis	29.81	11.55	126	62713	101916	110424544
Hyperuricaemia	29.81	11.55	39	62800	14492	110511968
Nocturia	29.42	11.55	42	62797	16948	110509512
Kidney transplant rejection	29.11	11.55	35	62804	11952	110514508
Hypochromasia	29.08	11.55	12	62827	700	110525760
Weight increased	28.48	11.55	132	62707	419512	110106948
Cardiac autonomic neuropathy	28.48	11.55	7	62832	71	110526389
Swollen tongue	28.30	11.55	87	62752	60275	110466185
Blister	28.14	11.55	54	62785	227322	110299138
Blood pressure ambulatory increased	28.13	11.55	7	62832	75	110526385
Night sweats	28.11	11.55	21	62818	133962	110392498
Haemodialysis	28.06	11.55	42	62797	17677	110508783
Injection site reaction	27.87	11.55	8	62831	89062	110437398
Anaemia	27.84	11.55	451	62388	546635	109979825
Sciatica	27.65	11.55	9	62830	92390	110434070
Lung diffusion test decreased	27.40	11.55	15	62824	1650	110524810
Hypomagnesaemia	27.37	11.55	86	62753	60284	110466176
Acute myocardial infarction	27.29	11.55	107	62732	83670	110442790
End stage renal disease	27.26	11.55	46	62793	21427	110505033
Phaeochromocytoma	27.10	11.55	12	62827	833	110525627
CADASIL	26.52	11.55	6	62833	41	110526419
Knee arthroplasty	26.39	11.55	3	62836	64945	110461515
Haematuria	26.22	11.55	105	62734	82900	110443560
Colitis ulcerative	26.02	11.55	6	62833	77357	110449103
Myalgia	25.70	11.55	215	62624	222166	110304294
Pulmonary embolism	25.66	11.55	209	62630	214265	110312195
Nephrogenic anaemia	25.47	11.55	21	62818	4556	110521904
Floppy iris syndrome	25.41	11.55	9	62830	345	110526115
Coronary artery disease	25.36	11.55	94	62745	71596	110454864
General physical health deterioration	25.32	11.55	140	62699	425155	110101305
Vertigo	25.17	11.55	107	62732	86763	110439697
Lower limb fracture	25.03	11.55	6	62833	75342	110451118
Actinic keratosis	24.90	11.55	25	62814	6988	110519472
Musculoskeletal pain	24.87	11.55	41	62798	182982	110343478
Subacute hepatic failure	24.81	11.55	8	62831	229	110526231
Inflammation	24.69	11.55	45	62794	193193	110333267
Subdural haematoma	24.54	11.55	60	62779	36394	110490066
Sprue-like enteropathy	24.43	11.55	14	62825	1682	110524778
Endoscopy upper gastrointestinal tract abnormal	24.31	11.55	6	62833	62	110526398
Autoimmune disorder	24.30	11.55	4	62835	65479	110460981
Left atrial enlargement	24.16	11.55	14	62825	1717	110524743
Adrenal cyst	23.99	11.55	8	62831	255	110526205
Thermal burn	23.92	11.55	26	62813	7962	110518498
Ischaemic cardiomyopathy	23.86	11.55	26	62813	7985	110518475
Prescribed overdose	23.73	11.55	10	62829	87571	110438889
Disease progression	23.71	11.55	66	62773	243968	110282492
Supine hypertension	23.29	11.55	9	62830	442	110526018
Hypertensive encephalopathy	22.99	11.55	12	62827	1199	110525261
Intervertebral disc space narrowing	22.98	11.55	14	62825	1882	110524578
Gravitational oedema	22.97	11.55	14	62825	1884	110524576
Proteinuria	22.94	11.55	62	62777	39956	110486504
Injection site inflammation	22.68	11.55	20	62819	4751	110521709
Wheezing	22.56	11.55	233	62606	254997	110271463
Mean platelet volume increased	22.46	11.55	13	62826	1591	110524869
Penile oedema	22.41	11.55	8	62831	314	110526146
Myopathy	22.32	11.55	46	62793	24914	110501546
Road traffic accident	22.31	11.55	17	62822	107381	110419079
Anuria	21.93	11.55	45	62794	24296	110502164
Glycosylated haemoglobin increased	21.67	11.55	44	62795	23575	110502885
Hypergastrinaemia	21.62	11.55	8	62831	348	110526112
Hepatosplenomegaly	21.56	11.55	23	62816	6896	110519564
Diabetic nephropathy	21.43	11.55	17	62822	3491	110522969
Obstruction	21.34	11.55	21	62818	5731	110520729
Hepatic cytolysis	21.26	11.55	3	62836	55050	110471410
Migraine	21.03	11.55	41	62798	171611	110354849
Blood glucose increased	20.94	11.55	138	62701	132358	110394102
Crush syndrome	20.81	11.55	8	62831	387	110526073
Blood pressure decreased	20.76	11.55	124	62715	114967	110411493
Arthralgia	20.72	11.55	315	62524	779317	109747143
Azotaemia	20.59	11.55	27	62812	10058	110516402
Ventricular extrasystoles	20.56	11.55	42	62797	22599	110503861
Dehydration	20.52	11.55	246	62593	279265	110247195
Angiosclerosis	20.36	11.55	4	62835	12	110526448
Diverticulum intestinal	20.33	11.55	29	62810	11690	110514770
Urinary retention	20.32	11.55	86	62753	69597	110456863
Hyperparathyroidism	20.20	11.55	17	62822	3793	110522667
Paraganglion neoplasm	20.14	11.55	5	62834	53	110526407
Mucosal membrane hyperplasia	20.06	11.55	5	62834	54	110526406
Cardiospasm	20.06	11.55	19	62820	4948	110521512
Duplicate therapy error	19.99	11.55	8	62831	431	110526029
Mean cell volume increased	19.70	11.55	24	62815	8306	110518154
Sinus node dysfunction	19.69	11.55	25	62814	9022	110517438
Transient ischaemic attack	19.47	11.55	80	62759	63902	110462558
Injection site erythema	19.45	11.55	15	62824	94161	110432299
Hip arthroplasty	19.44	11.55	4	62835	55809	110470651
Drug hypersensitivity	19.32	11.55	165	62674	453925	110072535
Fasting	19.28	11.55	5	62834	64	110526396
Pregnancy	19.22	11.55	3	62836	51064	110475396
Drug monitoring procedure not performed	19.21	11.55	11	62828	1319	110525141
Lower urinary tract symptoms	18.90	11.55	8	62831	498	110525962
Hypotensive crisis	18.53	11.55	6	62833	174	110526286
Nephrogenic systemic fibrosis	18.47	11.55	19	62820	5464	110520996
Psoriasis	18.43	11.55	32	62807	139961	110386499
Bundle branch block left	18.24	11.55	29	62810	12859	110513601
Coronary artery stenosis	18.17	11.55	30	62809	13728	110512732
Toxic neuropathy	18.16	11.55	10	62829	1113	110525347
Electrocardiogram T wave inversion	17.91	11.55	19	62820	5661	110520799
Spinal osteoarthritis	17.81	11.55	37	62802	20146	110506314
Blood chloride increased	17.80	11.55	20	62819	6352	110520108
Prostatic haemorrhage	17.80	11.55	6	62833	198	110526262
Electrocardiogram T wave peaked	17.60	11.55	10	62829	1182	110525278
Vertebrobasilar insufficiency	17.55	11.55	7	62832	374	110526086
Nausea	17.52	11.55	552	62287	1235138	109291322
Blood creatine phosphokinase increased	17.43	11.55	85	62754	72992	110453468
Priapism	17.42	11.55	19	62820	5842	110520618
Back injury	17.35	11.55	3	62836	47396	110479064
Spermatozoa progressive motility abnormal	17.35	11.55	4	62835	30	110526430
Device related bacteraemia	17.31	11.55	10	62829	1220	110525240
International normalised ratio increased	17.29	11.55	96	62743	86676	110439784
Gait inability	17.21	11.55	32	62807	136344	110390116
Hypocalcaemia	17.03	11.55	78	62761	65288	110461172
Drug ineffective for unapproved indication	17.00	11.55	20	62819	102818	110423642
Palmoplantar keratoderma	16.95	11.55	18	62821	5369	110521091
Atrioventricular block complete	16.78	11.55	36	62803	20046	110506414
Shock hypoglycaemic	16.72	11.55	6	62833	239	110526221
Cerebral infarction	16.71	11.55	66	62773	51772	110474688
Exostosis	16.63	11.55	3	62836	45953	110480507
Clang associations	16.61	11.55	4	62835	37	110526423
Toxic optic neuropathy	16.60	11.55	10	62829	1318	110525142
Head injury	16.57	11.55	58	62781	42959	110483501
Blood uric acid abnormal	16.48	11.55	7	62832	439	110526021
Prostatism	16.42	11.55	5	62834	118	110526342
Electrocardiogram ST segment elevation	16.38	11.55	23	62816	9137	110517323
Lethargy	16.35	11.55	100	62739	93476	110432984
Swelling face	16.35	11.55	99	62740	92222	110434238
Dermatosis	16.28	11.55	9	62830	1009	110525451
Chronic obstructive pulmonary disease	16.23	11.55	112	62727	109046	110417414
High density lipoprotein decreased	16.03	11.55	18	62821	5715	110520745
Renal tubular atrophy	16.03	11.55	12	62827	2264	110524196
Gastrointestinal haemorrhage	16.02	11.55	154	62685	165364	110361096
Liver function test increased	15.99	11.55	16	62823	88532	110437928
Oral discharge	15.82	11.55	6	62833	280	110526180
Muscle twitching	15.80	11.55	45	62794	29890	110496570
Product residue present	15.77	11.55	15	62824	3926	110522534
Pruritus genital	15.76	11.55	19	62820	6503	110519957
Post cardiac arrest syndrome	15.74	11.55	4	62835	47	110526413
Bursitis infective	15.62	11.55	10	62829	1466	110524994
Urine glucose/creatinine ratio increased	15.54	11.55	5	62834	142	110526318
Phaeochromocytoma crisis	15.53	11.55	7	62832	507	110525953
Venous thrombosis limb	15.53	11.55	17	62822	5248	110521212
Injection site pruritus	15.32	11.55	5	62834	51253	110475207
Acidosis	15.07	11.55	37	62802	22494	110503966
Joint swelling	15.02	11.55	170	62669	442675	110083785
Rectal haemorrhage	14.99	11.55	118	62721	119715	110406745
Bronchiolitis	14.94	11.55	17	62822	5476	110520984
Myelosuppression	14.91	11.55	19	62820	94321	110432139
Atrial tachycardia	14.89	11.55	22	62817	9156	110517304
Palpitations	14.85	11.55	147	62692	159065	110367395
Laryngitis	14.85	11.55	3	62836	42408	110484052
Cerebrovascular accident	14.84	11.55	163	62676	181121	110345339
Bradyphrenia	14.72	11.55	25	62814	11703	110514757
Fatigue	14.72	11.55	554	62285	1215404	109311056
Decreased ventricular preload	14.72	11.55	4	62835	62	110526398
Illness	14.67	11.55	15	62824	82156	110444304
Disorientation	14.63	11.55	79	62760	70592	110455868
Ventricular hypertrophy	14.60	11.55	19	62820	7026	110519434
Kidney fibrosis	14.40	11.55	15	62824	4377	110522083
Liver injury	14.37	11.55	41	62798	150372	110376088
Angina unstable	14.36	11.55	30	62809	16402	110510058
Septic shock	14.28	11.55	44	62795	157484	110368976
Tension headache	14.11	11.55	22	62817	9596	110516864
Herpes zoster	14.06	11.55	25	62814	108354	110418106
Sleep terror	13.96	11.55	18	62821	6592	110519868
Prescribed underdose	13.95	11.55	10	62829	65164	110461296
Asthenia	13.91	11.55	500	62339	688499	109837961
Swelling of eyelid	13.87	11.55	18	62821	6635	110519825
Injury	13.71	11.55	53	62786	177212	110349248
Tachyarrhythmia	13.69	11.55	20	62819	8241	110518219
Cardiomegaly	13.67	11.55	42	62797	29088	110497372
Mucosal inflammation	13.56	11.55	21	62818	96120	110430340
Epistaxis	13.47	11.55	123	62716	130249	110396211
Simple partial seizures	13.46	11.55	8	62831	1028	110525432
Genital swelling	13.38	11.55	6	62833	429	110526031
Aortic valve sclerosis	13.33	11.55	10	62829	1893	110524567
Sedation	13.28	11.55	12	62827	69671	110456789
Contusion	13.24	11.55	78	62761	233283	110293177
Haemophilus bacteraemia	13.13	11.55	5	62834	236	110526224
Drug dependence	13.09	11.55	6	62833	50014	110476446
Skin exfoliation	13.07	11.55	90	62749	87561	110438899
Ear pain	13.01	11.55	7	62832	53219	110473241
Blood uric acid increased	12.99	11.55	34	62805	21495	110504965
Hypoaesthesia	12.99	11.55	115	62724	314108	110212352
Muscular dystrophy	12.99	11.55	5	62834	243	110526217
Aortic dissection	12.96	11.55	15	62824	4918	110521542
Acquired apparent mineralocorticoid excess	12.88	11.55	4	62835	101	110526359
Oliguria	12.87	11.55	31	62808	18626	110507834
Carotid artery occlusion	12.82	11.55	21	62818	9544	110516916
Polyuria	12.80	11.55	30	62809	17708	110508752
Pemphigoid	12.80	11.55	32	62807	19675	110506785
Inappropriate schedule of product administration	12.68	11.55	66	62773	203571	110322889
Accelerated hypertension	12.62	11.55	7	62832	790	110525670
Shock	12.54	11.55	62	62777	53526	110472934
Tooth avulsion	12.52	11.55	4	62835	111	110526349
Product monitoring error	12.51	11.55	20	62819	8907	110517553
Blood pressure fluctuation	12.47	11.55	79	62760	74745	110451715
Hyperglycaemia	12.47	11.55	87	62752	85003	110441457
Pollakiuria	12.46	11.55	54	62785	44141	110482319
Feeling cold	12.38	11.55	45	62794	33942	110492518
Psychotic symptom	12.31	11.55	13	62826	3854	110522606
Malignant hypertension	12.29	11.55	9	62830	1642	110524818
Benign bone neoplasm	12.23	11.55	4	62835	120	110526340
Sepsis	12.17	11.55	123	62716	327223	110199237
Inappropriate affect	12.06	11.55	9	62830	1690	110524770
Visual field defect	12.03	11.55	21	62818	10051	110516409
Anaphylactoid reaction	12.00	11.55	17	62822	6809	110519651
Gastric ulcer haemorrhage	11.99	11.55	21	62818	10073	110516387
Mouth breathing	11.95	11.55	5	62834	302	110526158
Face oedema	11.93	11.55	44	62795	33425	110493035
Hyperlipidaemia	11.85	11.55	46	62793	35802	110490658
Periorbital oedema	11.85	11.55	21	62818	10171	110516289
Jaundice hepatocellular	11.84	11.55	4	62835	133	110526327
Ventricular tachycardia	11.81	11.55	58	62781	49951	110476509
Neuropathy peripheral	11.79	11.55	57	62782	179220	110347240
Blood glucose abnormal	11.78	11.55	24	62815	12892	110513568
Upper gastrointestinal haemorrhage	11.75	11.55	58	62781	50038	110476422
Dilatation ventricular	11.75	11.55	13	62826	4062	110522398
Anti-erythropoietin antibody negative	11.74	11.55	5	62834	316	110526144
Male sexual dysfunction	11.74	11.55	5	62834	316	110526144
Ejaculation disorder	11.70	11.55	6	62833	578	110525882
Metabolic myopathy	11.67	11.55	4	62835	139	110526321
Human polyomavirus infection	11.59	11.55	9	62830	1793	110524667
Nasal congestion	11.59	11.55	24	62815	98258	110428202
Bundle branch block	11.58	11.55	9	62830	1794	110524666
Pyrexia	11.58	11.55	406	62433	897859	109628601

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02CA04	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Alpha-adrenoreceptor antagonists
ATC	G04CA55	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
FDA EPC	N0000175553	alpha-Adrenergic Blocker
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35620	vasodilator agent
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:37890	α-adrenergic antagonist
CHEBI has role	CHEBI:59844	antihyperplasia drug
CHEBI has role	CHEBI:176497	geroprotector
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists

Related Drugs by ATC class:

C02CA Alpha-adrenoreceptor antagonists 4 drugs

indoramin prazosin trimazosin urapidil

G04CA Alpha-adrenoreceptor antagonists 8 drugs

alfuzosin dutasteride finasteride silodosin solifenacin tadalafil tamsulosin terazosin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Benign prostatic hyperplasia	indication	266569009
Priapism	contraindication	6273006	DOID:9286
Stenosis of intestine	contraindication	23065003
Orthostatic hypotension	contraindication	28651003
Low blood pressure	contraindication	45007003
Hepatic failure	contraindication	59927004
Chronic idiopathic constipation	contraindication	82934008
Cataract surgery	contraindication	110473004
Disease of liver	contraindication	235856003	DOID:409
Pyloric obstruction	contraindication	244815007
Syncope	contraindication	271594007
Intraoperative floppy iris syndrome	contraindication	418801006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.22	Basic
pKa2	0.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	8.85	WOMBAT-PK	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	9.10	WOMBAT-PK	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	ANTAGONIST	Ki	8.80	WOMBAT-PK	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.23	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	5	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.85	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.63	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.55	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.55	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.83	DRUG MATRIX
Interstitial collagenase	Enzyme	P03956	MMP1_HUMAN		IC50	5.24	DRUG MATRIX
HLA class I histocompatibility antigen, A-3 alpha chain	Surface antigen	P04439	1A03_HUMAN		Kd	4.80	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	5.72	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.14	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	9.38	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	8.81	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.90	DRUG MATRIX

External reference:

ID	Source
4019735	VUID
N0000147827	NUI
D00608	KEGG_DRUG
77883-43-3	SECONDARY_CAS_RN
4019565	VANDF
4019735	VANDF
C0114873	UMLSCUI
CHEBI:4708	CHEBI
CHEMBL707	ChEMBL_ID
CHEMBL1200561	ChEMBL_ID
D017292	MESH_DESCRIPTOR_UI
DB00590	DRUGBANK_ID
7170	IUPHAR_LIGAND_ID
5143	INN_ID
NW1291F1W8	UNII
3157	PUBCHEM_CID
39173	RXNORM
37806	MMSL
40546	MMSL
4637	MMSL
d00726	MMSL
003561	NDDF
004493	NDDF
108556006	SNOMEDCT_US
108557002	SNOMEDCT_US
372508002	SNOMEDCT_US
NW1291F1W8	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2410	TABLET	1 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2512	TABLET	2 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2614	TABLET	4 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2716	TABLET	8 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2750	TABLET	1 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2760	TABLET	2 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2770	TABLET	4 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2780	TABLET	8 mg	ORAL	NDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2067	TABLET	8 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2068	TABLET	4 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2069	TABLET	2 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2070	TABLET	1 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0356	TABLET	1 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0356	TABLET	1 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0357	TABLET	2 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0357	TABLET	2 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1358	TABLET	4 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1358	TABLET	4 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1359	TABLET	8 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1359	TABLET	8 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5522	TABLET	1 mg	ORAL	ANDA	18 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5523	TABLET	2 mg	ORAL	ANDA	18 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5524	TABLET	4 mg	ORAL	ANDA	18 sections
Doxazosin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-292	TABLET	4 mg	ORAL	ANDA	24 sections
Doxazosin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-629	TABLET	1 mg	ORAL	ANDA	24 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	16571-165	TABLET	1 mg	ORAL	ANDA	23 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	16571-166	TABLET	2 mg	ORAL	ANDA	23 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	16571-167	TABLET	4 mg	ORAL	ANDA	23 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	16571-168	TABLET	8 mg	ORAL	ANDA	23 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	16590-274	TABLET	4 mg	ORAL	ANDA	12 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

doxazosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: